PQ Bypass
- Company typePrivate
- Founded2009
- HeadquartersSunnyvale, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PQ Bypass does
PQ Bypass is a privately held medical device company founded in 2009 and headquartered in Sunnyvale, California. According to its firmographic profile, the company focuses on advancing the treatment of long-segment peripheral artery disease (PAD), a vascular condition affecting blood flow to the extremities. The company positions itself around "Organized Vascular Solutions," suggesting a device-based interventional approach to treating complex arterial lesions that are not well served by conventional endovascular therapies.
The company operates at a small scale, with 11–50 employees per firmographic data, consistent with a clinical or pre-commercial medtech venture. PQ Bypass has secured approximately $70 million in cumulative disclosed funding across at least two rounds (2016 and 2019), led by Deerfield Capital Management with participation from MedTech Venture Partners and Seroba Life Sciences — investors with established track records in medtech. Leadership consists of co-founders Richard Heuser and James Joye, supported by a Director of Clinical Field Operations.
The company's own website (pqbypass.com) currently hosts generic, low-quality content largely unrelated to its core medtech mission, including an article on Clinically Integrated Networks and numerous spam-like outbound links; this signals either a neglected digital presence, a website compromise, or a dormant marketing posture. No commercial revenue, customer logos, pricing, or detailed product specifications are disclosed in the source material, indicating the company is in a pre-commercial or early-clinical stage where disclosure is typically limited.
PQ Bypass firmographics
Firmographics- Name
- PQ Bypass
- Website
- https://pqbypass.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where PQ Bypass is headquartered
LocationHeadquarters
- HQ city
- Sunnyvale
- HQ country
- United States
- HQ region
- North America
Markets served
PQ Bypass business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
PQ Bypass product offering
Product offeringCore offering
PQ Bypass is a medtech company that develops interventional medical device systems for the treatment of long-segment peripheral artery disease. The company's technology enables percutaneous femoropopliteal bypass procedures, providing an endovascular alternative for patients with long-segment superficial femoral artery disease. The products are sold to hospitals and vascular specialists for use in minimally invasive vascular interventions.
Product overview
PQ Bypass offers a clinically integrated network (CIN) platform for healthcare providers and hospitals. The platform enables healthcare organizations to coordinate patient care by sharing information, protocols, and functional goals across a network of providers. The CIN solution helps reduce healthcare costs, decrease redundant services, and improve patient outcomes through better care coordination among pharmacists, behavioral health specialists, and other healthcare disciplines.
Differentiator
Problem solved
Functional benefit
Products and services
- Percutaneous Femoropopliteal Bypass System for Long-Segment Peripheral Artery Disease An interventional medical device system used by vascular surgeons and interventional cardiologists to perform a minimally invasive, percutaneous femoropopliteal bypass for patients with long-segment superficial femoral artery disease that is not adequately treated by standard angioplasty or stenting.
Companies that use PQ Bypass
Customer profileIdeal customer profiles1 record
PQ Bypass technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
PQ Bypass partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
PQ Bypass competitors and assessment
Company assessmentDirect peers
- Cardiovascular Systems (CSI): Cardiovascular Systems developed orbital atherectomy systems for peripheral artery disease. Directly comparable peripheral vascular intervention company addressing PAD with a focused specialty device platform.
- Inari Medical: Inari Medical develops catheter-based thrombectomy devices for venous thromboembolism. Comparable as a growth-stage peripheral vascular intervention company pursuing novel catheter-based approaches to underserved vascular disease segments.
- Silk Road Medical: Silk Road Medical develops minimally invasive devices for vascular disease (TCAR for carotid artery disease). Directly comparable as a small-cap, single-platform peripheral/carotid vascular intervention company with a focused specialty device franchise.
- Penumbra: Penumbra makes catheter-based thrombectomy and embolization devices for peripheral vascular conditions. Comparable peripheral vascular intervention company with a similar catheter-based, minimally invasive procedural focus.
Broad incumbents
- Boston Scientific: Boston Scientific's peripheral interventions franchise covers drug-eluting stents, atherectomy, and specialty balloons across SFA, popliteal, and below-the-knee disease. Comparable incumbent with overlapping peripheral vascular device portfolio and broad sales reach.
- Abbott Vascular: Abbott's vascular division offers a broad peripheral intervention portfolio (stents, drug-coated balloons, atherectomy, imaging). Comparable as a dominant incumbent in the peripheral vascular space against whose PQ Bypass's long-segment PAD device would compete commercially.
- Surmodics: Surmodics has a peripheral vascular intervention portfolio including drug-coated balloon technology. Comparable as an incumbent supplier of surface-coating and delivery technologies used in peripheral vascular devices.
- Medtronic: Medtronic's Peripheral Vascular Health business offers a comprehensive portfolio across PAD, including drug-coated balloons and stents. Comparable as a major incumbent defining standard of care in peripheral vascular intervention.
Emerging players
- LimFlow SA: LimFlow developed a percutaneous deep vein arterialization system for chronic limb-threatening ischemia. Comparable as a small, focused peripheral vascular company addressing underserved end-stage PAD with novel catheter-based technology.
- Reflow Medical: Reflow Medical develops specialty catheter systems for peripheral vascular disease, including dedicated technologies for complex lesions. Comparable as a smaller peripheral vascular device innovator addressing complex PAD anatomies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights4 records
Customer concentration
PQ Bypass social profiles
Digital presencePQ Bypass financial estimates
Financial estimateRevenue estimate
Valuation estimate
PQ Bypass leadership team
Management profileNumber of profiles
Profiles3 records
PQ Bypass funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PQ Bypass M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PQ Bypass
What does PQ Bypass do?
PQ Bypass is a medtech company that develops interventional medical device systems for the treatment of long-segment peripheral artery disease. The company's technology enables percutaneous femoropopliteal bypass procedures, providing an endovascular alternative for patients with long-segment superficial femoral artery disease. The products are sold to hospitals and vascular specialists for use in minimally invasive vascular interventions.
When was PQ Bypass founded?
PQ Bypass was founded in 2009. It employs 11 to 50 people.
Where is PQ Bypass based?
PQ Bypass is headquartered in Sunnyvale, United States, in the North America region.
Who are PQ Bypass's main competitors?
Direct peers on record are Cardiovascular Systems (CSI), Inari Medical, Silk Road Medical and Penumbra. Broad incumbents are Boston Scientific, Abbott Vascular, Surmodics and Medtronic. Emerging players are LimFlow SA and Reflow Medical.
Does PQ Bypass have an API?
No public API is recorded for PQ Bypass.